

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/162634/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Leibenluft, Ellen, Allen, Laura, Althof, Robert, Brotman, Melissa, Burke, Jeffrey, Carlson, Gabrielle, Dickstein, Daniel, Dougherty, Lea, Evans, Spencer, Kircanski, Katharina, Klein, Daniel, Malone, Eleanor, Mazefsky, Carla, Nigg, Joel, Perlman, Susan, Pine, Daniel, Krain Roy, Amy, Salum, Giovanni, Shakeshaft, Amy, Silver, Jamilah, Stoddard, Joel, Thapar, Anita, Tseng, Wan-Ling, Vidal-Ribas, Pablo, Wakschlag, Lauren and Stringaris, Argyris 2024. Irritability in youths: A critical integrative review. *The American Journal of Psychiatry* 181 (4), pp. 275-290. 10.1176/appi.ajp.20230256

Publishers page: <https://doi.org/10.1176/appi.ajp.20230256>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



Abstract: 233 words
Text: 5,619 words
References: 4,149 words
Tables: 4

Irritability in Youth: A Critical Integrative Review

Ellen Leibenluft, M.D., Laura E. Allen, M.D., Robert R. Althoff, M.D., Ph.D., Melissa A. Brotman, Ph.D., Jeffrey D. Burke, Ph.D., Gabrielle A. Carlson, M.D., Daniel P. Dickstein, M.D., Lea R. Dougherty, Ph.D., Spencer C. Evans, Ph.D., Katharina Kircanski, Ph.D., Daniel N. Klein, Ph.D., Eleanor P. Malone, B.A., Carla A. Mazefsky, Ph.D., Joel Nigg, Ph.D., Susan B. Perlman, Ph.D., Daniel S. Pine, M.D., Amy Krain Roy, Ph.D., Giovanni A. Salum, M.D., Ph.D., Amy Shakeshaft, Ph.D., Jamilah Silver, M.A., Joel Stoddard M.D., MAS, Anita Thapar, M.D., Ph.D., F.R.C. Psych, Wan-Ling Tseng, Ph.D., Pablo Vidal-Ribas, Ph.D., Lauren S. Wakschlag, Ph.D., Argyris Stringaris, M.D., Ph.D., F.R.C. Psych

Author and Article Information

Primary section authors: Introduction, Conclusion, Translational Research: Leibenluft, Stringaris; *Definition and Conceptualization:* Leibenluft, Carlson, Stringaris; *Measurement:* Althoff, Evans; *Epidemiology:* Vidal-Ribas, Burke; *DSM-5 and beyond:* Salum, Pine; *Early Childhood:* Perlman, Wakschlag; *Middle Childhood/Adolescence:* Klein, Silver, Dougherty; *Comorbidity with Neurodevelopmental Disorders:* Mazefsky, Nigg; *Treatment:* Stoddard, Brotman, Dickstein, Allen; *Neuroimaging:* Kircanski, Roy, Tseng; *Genetics:* Thapar, Shakeshaft.

Corresponding author: Ellen Leibenluft, M.D. leibs@mail.nih.gov

Affiliations:

Emotion and Development Branch, National Institute of Mental Health, Bethesda MD (*Leibenluft, Brotman, Kircanski, Malone, Pine*); Departments of Psychiatry, Pediatrics, & Psychological Science, University of Vermont, Burlington, VT (*Althoff*); Department of Psychological Sciences, University of Connecticut, Storrs, CT (*Burke*); Division of Child and Adolescent Psychiatry, Department of Psychiatry, Stony Brook University, Stony Brook, NY (*Carlson*); Division of Child and Adolescent Psychiatry, McLean Hospital, Harvard Medical School, Belmont, MA (*Dickstein*); Department of Psychology, University of Maryland, College Park, MD (*Dougherty*); Department of Psychology, University of Miami, Coral Gables, FL (*Evans*); Departments of Psychology and Psychiatry, Stony Brook University, Stony Brook, NY (*Klein*); Departments of Psychiatry, Psychology, and Clinical and Translational Science, University of Pittsburgh, Pittsburgh PA (*Mazefsky*); Department of Psychiatry, Oregon Health and Science University, Portland OR (*Nigg*); Department of Psychology, Washington University at St. Louis, St. Louis, MO (*Perlman*); Department of Psychology, Fordham University, Bronx, NY (*Roy*); Child Mind Institute, New York, NY (*Salum*); Division of Psychological Medicine and Clinical Neurosciences, Wolfson Centre for Young People's Mental Health, Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, Wales, United Kingdom (*Shakeshaft, Thapar*);

Department of Psychology, Stony Brook University, Stony Brook, NY (*Silver*); Division of Child and Adolescent Mental Health, Children's Hospital Colorado, University of Colorado School of Medicine, Denver, CO (*Stoddard*); Yale Child Study Center, Yale School of Medicine, New Haven, CT (*Tseng*); Child and Adolescent Mental Health Research Group, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain (*Vidal-Ribas*); Department of Medical Social Sciences, Institute for Innovations in Developmental Sciences, Institute for Policy Research, Northwestern University, Chicago, IL (*Wakschlag*); Faculty of Brain Sciences, Division of Psychiatry and Psychology and Language Sciences, University College London, London, UK (*Allen, Stringaris*) and First Department of Psychiatry, Aiginiteion Hospital, National & Kapodistrian University of Athens, Athens, Greece (*Stringaris*)

Disclosures:

Dr. Althoff is a founder and receives royalties from WISER Systems, LLC. He receives honoraria from the MGH Psychiatry Academy and *the Journal of the American Academy of Child and Adolescent Psychiatry*.

Dr. Roy receives book royalties from Oxford University Press, Springer Publishing

Prof Stringaris receives royalties from Oxford and Cambridge University Press and co-developed the Affective Reactivity Index (ARI), an open-source irritability measurement scale.

Funding Acknowledgment:

Dr. Leibenluft, Dr. Kircanski, Ms. Malone: NIMH Intramural Research Program (IRP) ZIAMH002786; *Dr. Brotman:* NIMH IRP ZIA MH002969; *Drs. Carlson and Klein:* NIMH R01MH069942; *Dr. Dickstein:* NIMH R01MH110379, NIMH R01MH111542, NIMH K24MH110402, Charles H. Hood Foundation Major Grant; *Dr. Mazefsky:* NICHD R01HD079512 and NIMH P50 MH130957; *Dr. Nigg:* NIMH R01MHR3759105; *Dr. Perlman:* NIMH R01MH124266 and R01MH130007; *Dr. Pine:* NIMH IRP ZIAMH002781; *Drs. Shakeshaft and Thapar:* Wolfson Foundation; *Dr. Silver:* National Science Foundation Graduate Research Fellowship Program 16-588; *Dr. Stoddard:* NIMH K23MH113731, Brain and Behavioral Research Foundation, Children's Colorado Hospital Foundation; *Dr. Tseng:* NIMH R00MH110570), Charles H. Hood Foundation, Fund to Retain Clinical Scientists from Yale School of Medicine and Yale Center for Clinical Investigation; *Dr. Vidal-Ribas:* Grant RYC2021-033369-I from MCIN/AEI/10.13039/501100011033 and the European Union «NextGenerationEU/PRTR»; *Dr. Wakschlag:* NIMH R01MH107652; *Dr. Stringaris:* NIMH IRP ZIA MH002957, University College London

Abstract

Irritability, defined as proneness to anger that may reach an impairing extent, is common in youth. There has been a recent upsurge in relevant research. We combine systematic and narrative review approaches to integrate the latest clinical and translational findings and provide suggestions to address research gaps.

Clinicians and researchers should assess irritability routinely; specific assessment tools are now available. Informant effects are prominent, stable, and vary by age and gender. The prevalence of irritability is particularly high in attention deficit hyperactivity disorder, autism spectrum disorder, and mood and anxiety disorders. Irritability is associated with impairment and suicidality risk independent of co-occurring diagnoses.

Irritability trajectories have been identified that are differentially associated with clinical outcomes; some begin early in life. Youth irritability is associated with increased risk later in life for anxiety, depression, behavioral problems, and suicidality. Irritability is moderately heritable and genetic associations differ based on age and comorbid illnesses. Parent management training is effective for constructs related to irritability, but its efficacy in irritability should be tested rigorously, as should novel mechanism-informed interventions (e.g., those targeted to frustration exposure).

Associations between irritability and suicidality and the impact of cultural context are important, under-researched topics. Large, diverse, longitudinal samples that extend into

adulthood are needed. Data from both animal and human research indicate that aberrant responses to frustration and threat are central to the pathophysiology of irritability, thus affording important translational opportunities.

Introduction

Here we present a review of the literature on irritability in youth by clinical researchers with a broad range of expertise. Why is pediatric irritability important, and why is an integrative review warranted now?

Irritability can be defined as proneness to anger that may reach an impairing extent. It is one of the most common reasons that youth present for mental health evaluation and care (1). The most salient feature of clinically relevant irritability is frequent temper outbursts that are developmentally inappropriate and out of proportion to a precipitating event (phasic irritability (2)). Such outbursts are typically accompanied by chronic grouchiness and angry mood (tonic irritability); for case descriptions, see (3). Severe irritability is associated with impairment at home, in school, and with peers (2). It is a central symptom of three Diagnostic and Statistical Manual for Mental Disorders (DSM-5) diagnoses (*DSM-5 and beyond*) as well as a transdiagnostic, dimensional construct that is especially common in attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and anxiety and mood disorders (4–6).

Irritability is a negative valence phenotype characterized by approach behavior (7). Etiologically, it has moderate heritability (*Genetics*), is associated with environmental adversities including peer victimization (8) and adverse childhood experiences (9,10) and can follow several different developmental trajectories (*Epidemiology*). One model of irritability proposes two potential mechanisms: difficulty tolerating frustration (i.e., the emotional and behavioral response to

omission of an expected or desired reward; frustrative non-reward, (FNR) in the Research Domain Criteria (RDoC)) and aggressive responses to threat (7). This model has been elaborated to specify intervention targets (11) and can be studied in animals (*Translational Research*) (7).

The number of publications focused on irritability per year has quadrupled since 2000 (12).

Nonetheless, irritability remains understudied relative to its clinical importance. We present the latest clinical and translational findings and identify research gaps. Depending on the content of each section of the review, we performed systematic reviews, relied on prior reviews and metaanalyses, and/or used narrative methodology (*Supplement: Search methods*). Four sections focus on foundational topics; three on specific developmental periods or comorbidities; one on treatment; and three on methods and mechanisms. Each section concludes with prioritized suggestions for future research (also see Table 1).

Definition and conceptualization

Irritability has both mood (13) and behavioral components. It can be differentiated from related constructs, specifically emotion dysregulation (ED, (2)); the latter is a broader construct encompassing multiple emotional phenotypes including surgency, anxiety, mania, depression, and others (5). Questionnaire data indicate that irritability can be differentiated psychometrically from ED (14), anger and aggression (15). Irritability is also unique in that it is associated with both externalizing (16) and internalizing problems (*Epidemiology; Genetics*)¹.

¹This review focuses on literature studying irritability. However, under *Comorbidity with Neurodevelopmental Conditions and Treatment*, we also include literature studying ED or externalizing disorders because, in these subfields, irritability is usually not differentiated from these other constructs.

Beyond defining irritability as distinct from other constructs, it is important to test its external validity i.e., its ability to reliably provide relevant clinical information (17,18). Kendler (17) suggests assessing external validity using familial aggregation; illness course; stability; and treatment response. As detailed below, the main indicators of external validity for irritability are its moderate heritability (19–21); illness course data (i.e., longitudinal associations with anxiety, depressive disorders, behavioral problems and suicidality (5,22,23); and its ability to predict future impairment and psychopathology beyond that of comorbid disorders (4,24–26).

Irritability waxes and wanes; research on diagnostic criteria for bipolar disorder (BD) in youth demonstrates that such temporal heterogeneity is clinically important (27) (*DSM-5 and beyond*). There are two complementary approaches to characterizing the temporal course of irritability. The first references a lengthy time scale and differentiates *episodic* vs. *chronic* (trait) irritability. Episodic irritability is present for a delimited period. Its onset and offset are contemporaneous with changes in other characteristic symptoms (e.g., for mania, changes in sleep, activity, etc.). In contrast, chronic irritability is relatively constant.

The second subtyping approach has a shorter time scale. It differentiates acute temper outbursts (phasic irritability) vs. chronic angry mood (tonic irritability). Phasic and tonic irritability are highly correlated but may differ in comorbidities, genetic mechanisms, longitudinal course, and treatment response (28,29). Research into these associations is ongoing (*Middle Childhood/Adolescence*) as are studies of acute vs. sustained emotional

responses during paradigms inducing anger or frustration (30,31); these could elucidate mechanisms underlying phasic vs. tonic irritability.

Finally, there are individual differences in proneness to experiencing and exhibiting anger. For example, research suggests that inter-individual differences in the extent to which an environmental stimulus (e.g., another young person) is perceived as threatening influences angry, aggressive responses (32). However, such differences have not been explored from a first-person perspective with a deep qualitative understanding of how prior experiences and current context impact the experience of anger and subsequent behaviors. Regarding context, evidence suggests that individuals' anger expression is causally impacted by environmental affordances i.e., when the latter support fighting, anger is more likely to be expressed (33). This supports the importance of considering cultural and social demands. Indeed, the efficacy of parent management training (PMT) in clinical constructs related to irritability (*Treatment*) demonstrates that these are relevant (5,34,35). The mechanisms of these different effects could be studied using real-time digital phenotyping techniques (e.g., ecological momentary assessment (EMA), actigraphy) as well as fMRI paradigms evoking frustration and anger in a social context.

The highest priority research questions regarding the conceptualization of irritability involve extending current work on the external and incremental validity of the construct and refining its definition based on these data. This effort should be cross-cultural and overlaps significantly with other research suggestions below.

Measurement

Initial advances in irritability research relied on secondary analyses of symptom data from large datasets (36). Post-hoc irritability scales were derived from structured (e.g., Development and Well-Being Assessment, DAWBA (37)) and semi-structured DSM-based interviews (e.g., Schedule for Affective Disorders and Schizophrenia for School-Age Children, K-SADS (38)), parent- and youth-report checklists (e.g., Child Behavior Checklist and Youth Self-Report, CBCL/YSR) and temperament rating scales, but these have psychometric limitations. Irritability has also been measured using items designed to assess specific diagnoses (e.g., disruptive behavior, mood, anxiety, stress disorders) (Table S1).

It is essential to have instruments that measure irritability specifically. Notable examples include ((5,39,40), Table S1): the Affective Reactivity Index (ARI); Clinician ARI; Multi-dimensional Assessment of Preschool Disruptive Behavior; Disruptive Behavior Diagnostic Observation Schedule; Emotion Dysregulation Inventory (EDI) Reactivity scale; and Emotional Outburst Inventory (EMO-I). When measuring irritability, it is important to consider “near neighbor” constructs (e.g., ED, anger, aggression) and co-occurring symptoms and disorders (e.g., depression, ADHD, traumatic stress, sleep disturbance) (5,41).

Multi-informant irritability studies show evidence of validity, reliability, and stability for both parent- and self-report; however, interrater agreement is modest and yields item- and scale-level differences (15,42). Such low agreement is common in youth psychopathology, likely

reflecting differences in perspective rather than measurement error (43). This evidence argues against averaging scores across informants or using a single informant. Researchers examining multiple informant data should parse informant variance (e.g., using bifactor or informant-specific models). Clinicians should also view informant discrepancies as potentially meaningful, explore them in detail, and consider parent and child reports as equally important sources of information (5,39). Finally, it is not uncommon for irritability to be reported by one informant, typically a parent, in the absence of corroborating reports. In such cases, the treating clinician should assess the reliability of the historian, clinical impairment and intervention options.

Inconsistent results have been reported in the neuroimaging and genetic literatures on irritability, possibly because of different assessment instruments (*Neuroimaging, Genetics*). Given the relatively nascent state of irritability research, it is premature to designate “gold standard” measures. However, a reasonable assessment might include an irritability-specific measure (e.g., ARI), outburst-specific measure (e.g., EMO-I), and a broad measure of psychopathology and regulation (e.g., CBCL and its dysregulation profile (44,45)). As data emerge on the reliability and external validity of different measures, the field could adopt consistent measures.

Future studies should investigate how symptom measures and their variation among informants relate to external validators, including cognitive and psychophysiological measures, longitudinal course, treatment response (5,10,15), passive sensor data, and *in vivo* real-time EMA from parent and child. Self-report measures differentiating tonic vs. phasic irritability, along with

developmentally- and culturally-sensitive idiographic and qualitative tools, would enable young people's perspectives to be better incorporated in care and research and help elucidate factors underlying observed informant effects (1). Scant literature describes how vulnerable populations (e.g., those marginalized or with neurodevelopmental conditions) experience or express irritability. Research combining qualitative and quantitative methods is key to addressing such issues of epistemic injustice.

Epidemiology

The frequency and intensity of normative irritable mood and temper outbursts varies developmentally, generally peaking in early childhood and declining into adulthood.

International data suggest that, from early childhood to early adolescence, 44% to 82% of individuals show low, stable levels of irritability (Table 2, (35,46–50)) while 2-5% of children show elevated and persistent or increasing irritability. Non-stable trajectories also exist; in one study, 5% of children experienced a curvilinear trajectory peaking in late childhood (48).

Vulnerable populations may show greater variability in developmental trajectories.

Evidence suggests complex interactions among age, gender, and informant in rating a child's irritability (42,48). Comparisons across studies are difficult because informants vary by subject age (e.g., parent ratings of young children vs. self, with or without parent, ratings in adolescence) and individual studies generally do not cover broad developmental periods.

Cross-sectionally, chronic irritability clusters with depression, anxiety, oppositional behavior, conduct disorder (CD), ADHD, and ASD (51). However, a meta-analysis of longitudinal studies found that irritability has the strongest links with depression (OR=1.80), anxiety (OR=1.72), and oppositional defiant disorder (ODD, OR=2.62); the latter might be inflated by item overlap (22). Irritability in youth is associated with suicidal thoughts and behaviors in community samples, both cross-sectionally (OR=1.08-4.40) and longitudinally, the latter especially if accompanied by depressive symptoms (OR= 1.15-2.22) (52).

Recent research identifies developmental trajectories of irritability. The highest priority for epidemiological research on irritability is related mechanistic studies and examinations of the continuity of irritability into adulthood. Studies should have multiple informants, including self-report in adolescents to avoid missing less overt symptoms, especially in girls. Finally, few studies have included underrepresented populations (for exceptions, see (35,53)).

DSM-5 and beyond

“Irritability” or “anger” appears in 20 conditions in the DSM-5, including disorders characterized by aggression. Episodic irritability occurs during manic episodes, depressive episodes in youth, withdrawal syndromes, and Premenstrual Dysphoric Disorder. Chronic irritability manifests in multiple disorders, including Generalized Anxiety Disorder and Post-Traumatic Stress Disorder; is a cardinal symptom of Intermittent Explosive Disorder (IED), ODD, and Disruptive Mood Dysregulation Disorder (DMDD); and may be a major feature of neurodevelopmental disorders (*Comorbidity with neurodevelopmental conditions*).

We discuss three questions regarding irritability in DSM-5. One concerns the boundary between DMDD and mania. In the early 2000's, an emerging school of thought maintained that BD did not present in youth with distinct manic episodes, as in adults, but instead with non-episodic irritability and hyperarousal (54). Since the latter phenotype overlaps considerably with ADHD, there was an upsurge in the rate at which youth were assigned the diagnosis of BD (55). However, subsequent research revealed that chronic, non-episodic irritability in youth does not confer increased risk for mania later in life, indicating that the diagnosis of BD should be reserved for youth with distinct manic episodes (22,27). DMDD was included in DSM-5 to provide a diagnosis for children receiving the diagnosis of BD inappropriately. ICD-11 did not adopt DMDD, opting instead for a subtype of ODD (36). DMDD has had rapid uptake in clinical practice and was associated with reduced rates of BD diagnosis (56). However, patients with DMDD, like those with BD, have high rates of antipsychotic and polypharmacy prescriptions (56), perhaps reflecting the lack of specific, evidence-based therapeutic options.

A second question relates to boundaries among the three DSM-5 diagnoses in which chronic irritability is a core symptom i.e., IED, ODD, and DMDD. DMDD is classified as a depressive disorder, whereas ODD and IED are classified as disruptive/impulse-control disorders. Questions exist about the uniqueness of these syndromes, particularly given item overlap. Few studies compare them using external validators, including familial aggregation, outcome, and treatment response.

Third, the optimal threshold for differentiating pathological and subclinical irritability is unknown and likely to vary developmentally (57). Confusion about the threshold and the use of different assessment instruments likely contribute to the varying prevalence of DMDD across studies i.e., the reported prevalence varies 10-fold, with lower bounds below 0.5% and upper bounds above 8% (Table 3, (4,51,57–65)); notably, variation is also found in more established psychiatric disorders (66).

Within the DSM, the most important research priority is for cross-cultural epidemiological studies to derive data-driven thresholds for irritability (4) and facilitate harmonizing IED, ODD, and DMDD. Longitudinal studies could identify criteria for non-normative irritability based on outcome. External validity could be tested using family measures, physiological measures and treatment response.

Outside the DSM framework, a high priority research goal is integrating a dimensional perspective into diagnosis because the boundary between normative and pathological irritability is unlikely to be sharp. Dimensionalizing the multiple symptoms comprising, or frequently associated with, irritability (e.g., temper outbursts, reactive aggression) might help characterize the heterogeneous presentations of irritability and facilitate mechanistic studies. Dimensional approaches (i.e., Hierarchical Taxonomy of Psychopathology (HiTOP, (67), RDoC, (68)) presume that irritability-related symptoms are expressions of a shared liability or are hierarchically organized, with general psychopathology factors and lower-level domains and subfactors.

Early childhood

While all young children exhibit temper outbursts, individual differences in outbursts can be a transdiagnostic risk marker for later psychopathology. Studying such differences can aid in prevention. A recent meta-analysis found a small association between infant irritability and later internalizing and externalizing symptoms; for preschool irritability the associations were small-moderate (69). Specific markers of atypical irritability can be identified as early as 12 months of age and include dysregulation (e.g., tantrums till exhausted), occurrence in unexpected contexts (e.g., grumpy during fun activities), and high frequency (daily or more) (70). In one longitudinal study of children recruited at pediatric visits and oversampled for irritability (N=425; mean baseline age=4.7 years, mean follow-up= 2.9 years, 51% girls), low frustration tolerance and destructive tantrums at baseline were associated with impairment and DSM-5 diagnoses cross-sectionally and longitudinally (26). Repeated assessment was important because single assessments yielded frequent false positives but few false negatives (57). Secondary data analyses suggest that early irritability responds to interventions designed to promote early self-regulation e.g., (71,72).

Studying brain-behavior substrates of early irritability is challenging, but methodological advances have yielded interesting pilot data. One study using functional near-infrared spectroscopy (fNIRS) linked irritability to inter-dyadic differences in parent-child synchrony neurally and behaviorally (73); another found that irritability was inversely correlated with striatal and anterior cingulate activity during frustration (74).

The highest priority research aim would be developing tools that combine behavior patterns, neural biomarkers and parent-child interactional processes to identify which highly irritable young children will develop clinical problems and what malleable protective processes can be leveraged for prevention. Such tools could allow the integration of personalized prediction of risk into pediatric primary care (75). Improved early identification will enable the development of interventions designed to increase adaptive parent-child co-regulation.

Middle childhood/adolescence

Multiple community-based studies describe longitudinal developmental trajectories of irritability (*Epidemiology*, Table 1). One large study (N=4,462) followed a community sample of youth, oversampled for children of unmarried parents, from ages 3 to 15. Results showed that pre-adolescence and adolescence are important inflection points in several trajectories, and that harsh/neglectful parenting and internalizing symptoms differentiated groups (35).

Irritability in middle childhood and adolescence is often associated with co-occurring symptoms that complicate clinical care. Irritability can obscure internalizing psychopathology, raising questions about the primary treatment focus and whether treating the co-occurring problem could worsen the irritability. When irritability co-occurs with another syndrome or diagnosis, it is associated with increased impairment and a worse course (24,76).

Irritability confers risk for suicidality and non-suicidal self-injury, above major depressive disorder and other risk factors. Increased irritability often precedes suicidal behavior (46,77), particularly in the context of high irritability during middle childhood (78), and may be useful in detecting near-term risk. Mechanisms mediating associations between irritability and suicidality are unknown, although several models have been proposed (e.g., irritability as an endophenotype of suicidality, a risk factor for suicidality due to associations with other psychopathology, and/or a risk factor for the transition from suicidal ideation to attempt) (77).

In adolescence, irritability may play a role in increased mood problems and risk-taking behaviors including substance abuse. For instance, irritability mediates the association between ADHD and alcohol use problems (79), and temper outbursts (i.e., phasic irritability) predict substance use and risky sexual behaviors (29).

The highest-priority research questions revolve around suicidality. It is important to test whether interventions targeting irritability reduce suicidality and other clinical problems e.g., substance abuse, and to study mechanistic links between irritability and depression. Further research is warranted on longitudinal outcomes of tonic and phasic irritability (29,80), including mechanisms mediating those predictions. Given high correlations between tonic and phasic irritability, large samples will be needed. Finally, researchers should examine whether minority stressors are associated with increased youth irritability and suicidality, thus contributing to mental health disparities in sexual and gender minority youth and other marginalized populations.

Comorbidity with neurodevelopmental conditions

Youth with ADHD and ASD have high rates of irritability, often occurring in the context of more generalized ED i.e., excitability, anxiety, and lability. Over half of youth with ADHD or ASD have ED (6,16) and approximately 40% of youth with ADHD aged 7-12 experience extreme irritability; a similar proportion experience extreme surgency with more moderate irritability (16). ED, including irritability, is related to genetic liability for ADHD (16) (*Genetics*). Thus, ED may be a central feature of ADHD, complicating both assessment and treatment. Data suggest that variation in ED may form a basis for ADHD subtypes (16,81).

The clinical significance of irritability in ASD is illustrated by 45 clinical trials with irritability as the outcome (82). However, irritability is often defined to include self-injury and aggression, with insufficient focus on propensity to anger. There are few mechanistically focused studies on irritability in ASD. Some studies use tasks from ADHD research to examine frustration response and associated physiological arousal in ASD (83), but it is unknown whether factors influencing irritability are shared across ASD and ADHD. Irritability might stem from core symptoms such as inattention contributing to blocked goal attainment and frustration in ADHD, or violations of preference for sameness in ASD. However, given broad ED in both populations, cross-domain self-regulation difficulties (e.g., difficulties in top-down regulatory mechanisms) may play a larger role than diagnostic-specific features.

ADHD, ASD, and irritability all have an early onset (84). The highest-priority research question is whether irritability is a feature of those conditions versus an early indicator or risk factor of a secondary condition. Do alterations in the development of top-down control in early life influence both impulsivity and irritability? It is important to study the longitudinal course of irritability into adulthood in ADHD and ASD, including the impact of treatment and of the stresses of neurodevelopmental conditions.

Treatment

Evidence for the treatment of irritability is increasing, yet few randomized controlled trials (RCTs) use irritability as a primary or secondary outcome. Our systematic review (*Supplement: Systematic review of studies on treatment for irritability*, Fig. S1, Table S2) found 14 medication and/or psychological intervention studies in the past 5 years on the treatment of irritability (excluding those for ASD). However, most are at high risk of bias with either no control, or controls where unblinding is likely (Fig. S2). Here we also include information from publications prior to 2018; for these we used a narrative review approach (*Supplement: Search Methods*).

Parent management training (PMT) teaches parents reinforcement-based methods, reduces externalizing problems in youth younger than 13 years ($d \sim 0.5$), (34) and is scalable. Indeed, PMT's efficacy is substantial and comes from many trials of good quality. Considering PMT's efficacy across methods, cultures, and treatment settings (85), it should be studied explicitly in young people with irritability.

Cognitive Behavioral Therapy (CBT) shows medium effect sizes in children and adolescents with externalizing symptoms, disruptive and antisocial behavior, and anger-related problems; however, the studies were small and often included inactive comparators (86). Transdiagnostic CBT programs (e.g., MATCH, Unified Protocol) show promise (87), as do behavioral analysis and skills enhancement programs (88,89). Preliminary data support the potential efficacy of dialectical behavior therapy (82,90), interpersonal psychotherapy (83,91), and exposure-based treatments for irritability (84,92). Irritability may also be reduced as a secondary outcome in treatment whose primary target is another condition e.g., children who received exposure and response prevention CBT for their primary diagnosis of obsessive-compulsive disorder (93).

When irritability does not respond to behavioral interventions, medication augmentation is common. Risperidone and aripiprazole have an FDA indication for irritability in those with ASD. While extending these findings to those without ASD is often done, practitioners should do so with caution and ensure that non-pharmacological interventions have been maximized.

Concerns regarding generalizing the ASD literature include first, the irritability measure in these trials was designed for those with developmental disabilities (e.g., including self-harm items (94)). Second, medication side-effects (e.g., rapid weight gain) can lead to unblinding and inflated effect sizes and/or cause differences from placebo due to non-specific effects e.g., sedation. Finally, antipsychotic efficacy should be balanced against the high frequency and severity of side effects (95).

Secondary data analyses show that stimulants may reduce irritability in youth with ADHD (96). Thus, in children with ADHD and irritability, ADHD medication should be optimized first (5). Antidepressants may also be useful. A small trial in youth with DMDD and ADHD found citalopram plus methylphenidate reduced irritability more than placebo plus methylphenidate (97).

Clinically, the top priority is to conduct rigorous RCTs for children with severe irritability that does not improve when the primary diagnosis has been treated. Careful assessment of both efficacy and side effects is important in both pharmacological and psychological trials. Increased mechanistic work is essential. For example, studies testing whether irritability and ED respond differently to treatment would be clinically important and informative regarding the external validity of both constructs. As another example, intervention that exposes youth to anger-inducing events (92,98) builds on work showing predictive associations between irritability and aberrant brain reorganization after frustration (30), but the relevance of this mechanistic work to treatment response has not been tested. In-session psychological mechanisms (e.g., enhancing distress tolerance, habituation, extinction) should also be studied.

Neuroimaging

Neuroimaging research on irritability has increased but faces the challenges of reproducibility and small effect sizes seen in clinical neuroscience broadly ((99), Tables S2-4). A meta-analysis of 30 task-based fMRI studies showed no spatial convergence of neural activation associated with irritability across or within neurocognitive domains including emotional reactivity, cognitive

control, and reward processing (100). Studies of irritability and functional connectivity (FC) of brain regions during task or rest have yielded inconsistent results (101). The amygdala has been the focus of the largest number of FC studies, exhibiting mixed results. These inconsistent findings may reflect methodological variability and/or heterogeneity in associations between irritability and brain function. The literature on structural MRI is much smaller but has also shown inconsistent findings in grey or white matter volume or microstructure (100).

A few studies of irritability in preschoolers have used event-related potential (ERP) metrics of executive functioning, reward, or error processing (102). Further work should test constructs and ERP indices more consistently across development. A few fNIRS investigations of frustration and cognitive control find that preschoolers with irritability have lower prefrontal activity, suggesting more difficulty regulating frustration (103) (*Early Childhood*).

In sum, the neuroimaging literature on irritability is small, young, and inconclusive. Cross-sectional studies have not yielded neurobiological markers. Methodological adaptations could yield more promising results. First, neuroimaging researchers should employ developmentally-sensitive, multi-informant, and valid measures of irritability (*Measurement*). Second, existing cross-sectional studies can inform longitudinal studies of neural mechanisms underlying intra-individual changes in irritability due to development or treatment. Third, for fMRI studies, task designs that evoke relevant affective states (i.e., frustration) have increased ecological validity and evoke stronger emotional responses, and multivariate measures identified using machine learning are more reliable than those identified using univariate or single-region approaches,

improving rigor and reproducibility. For example, a recent pilot study using pre- and post-frustration resting-state scans found associations between irritability and post-frustration connectivity across limbic, reward, and sensorimotor networks (30), a finding that merits follow-up in future studies. Fourth, future work should capitalize on technological and analytic advances that integrate multiple modalities (e.g., EEG and fMRI) to probe interactions between underlying structural and functional connectivity and task-based responses at multiple timescales. Multisite collaborations will enable large sample sizes, internal and external validation, and more robust investigation of socioenvironmental factors including race/ethnicity, cultural context, and psychiatric comorbidity. Such robust investigations could identify mediators and moderators and differentiate more homogeneous subgroups. These methodological advancements could yield enhanced understanding of specific neurobiological mechanisms underlying irritability and guide development and testing of treatments with tractable neural targets (e.g., real-time fMRI neurofeedback or transcranial magnetic stimulation).

Genetics

Twin studies suggest that irritability is moderately heritable, with estimates ranging from 22% to 51% (21) (Table 4, (19–21,104,105)). Genetic contributions to irritability appear to be dynamic with stable genetic influences from childhood to adolescence and later, novel genetic and environmental influences (21). What is distinctive about genetic and environmental influences on irritability, and how do they inform our conceptualization?

First, the magnitude of heritability appears to differ across sexes, which is unusual. Heritability also increases for males and decreases for females from childhood to adolescence (21).

Second, genetically, a central question is whether irritability is best conceptualized as a) a mood problem, as in DSM-5; b) an ODD subtype, as in ICD-11; or c) closely related to ADHD and other neurodevelopmental disorders. An early twin study (19) showed that irritability predicted later depression and, unlike headstrong/hurtful ODD symptoms, showed genetic correlation with depression (0.70, 95% CI=0.59-0.82). This has been replicated, highlighting the distinction of irritable vs. headstrong/hurtful ODD symptoms. Non-shared environmental influences make a substantial contribution to irritability but shared environmental factors do not (19), while shared environment makes a substantial contribution to behavioral problems (106), again suggesting a distinction between the latter and irritability. However, a twin study of emotional lability, a construct comprised of irritability and mood volatility, showed substantial genetic overlap with ADHD (20), while other studies suggest irritability predicts and shows genetic overlap with antisocial behaviour (105). Therefore, the data are currently mixed and further research is needed.

Recent genetic investigations use composite measures of common genetic risk variants (polygenic scores, PGS). In a longitudinal, population-based study, an early-onset, persistent form of irritability was associated with ADHD PGS, male preponderance, and ADHD (48). A later, adolescent-onset increasing trajectory was associated with depression PGS, female

preponderance and adolescent depression. Also, a large cross-sectional study found that the ADHD PGS was associated with irritability, particularly global ED in youth with ADHD (107). These findings, together with twin studies, suggest that irritability is related to ADHD genetic liability, and that early-onset, male irritability may be more neurodevelopmental in origin and later-onset irritability more akin to other mood problems, although the groups overlap.

Finally, gene-environment correlations e.g., when genetically encoded child characteristics evoke parental irritability (evocative correlation), or when a child inherits not only genes but also the environment of irritable parents (passive correlation), are probably abundant in developmental psychology but are difficult to study (108). However, both clinical experience and developmental theory suggest that person-environment evocative correlations exist such that parent-child dyads engage in mutually coercive, angry cycles (109). Indeed, PMT's efficacy is thought to be predicated on breaking this cyclic reinforcement of aberrant behaviors, including irritability.

The highest priority goal would be to use longitudinal genetic designs to test whether irritability represents the same construct by gender, across ages, and in the context of different disorders (e.g., major depressive disorder vs ADHD). A related question is whether irritability indexes biological /genetic heterogeneity and could be a useful stratifier of treatment and prognosis. A third topic involves examining the genetic architecture of phasic vs. tonic irritability, given twin evidence suggesting differences (110). Detailed clinical enquiry among diverse patient groups

and large-scale genetic data can address clinically important questions on how best to conceptualize and treat irritability.

Translational research

Translational models guiding work bridging preclinical and clinical research on irritability center on two constructs: frustrative non-reward (FNR) and reactive aggression (RA).

FNR was first described by Amsel in rodents and since observed in multiple other species, including humans (7,111). FNR is the normative response to frustration, or blocked goal attainment; it can be viewed as one form of negative prediction error (11). The FNR response is characterized by increased activity, increased aggression (typically measured using the resident intruder test (112)), and resistance to extinction of conditioned responses. Data suggest that aberrant behavioral and neural responses to frustration are central to pediatric irritability (30,113), supporting the clinical relevance of FNR paradigms in animals.

Rodent studies induce FNR using operant conditioning followed by omission or diminution of the expected reward. Studies of the FNR response in adult animals implicate the central amygdala, as well as dopaminergic pathways in frontal cortex and ventral striatum (114,115) (98, 99). However, these paradigms often require lengthy training and mature motor skills, making them less applicable to juvenile animals (116,117). One new paradigm addresses these limitations by capitalizing on the mouse's tendency to explore two places alternately. This paradigm elicits the expected FNR responses in juvenile mice without affecting behavior on

tasks modelling anxiety, depression, or non-aggressive social behavior (118). Using this paradigm and C-fos expression, investigators found FNR-induced activation in multiple regions and a brain-wide shift toward a more integrated, network organization, broadly consistent with one human study (30). Future FNR studies in rodent models using techniques such as fiber photometry optogenetics (119) could guide human fMRI FNR studies.

In certain contexts, reactive aggression, (RA), or aggressive responses to threat, are adaptive (120). However, youth with irritability often have maladaptive or excessive aggressive responses to perceived threat and other negative stimuli (121–125). RA is defensive, characterized by impulsivity, and associated with emotional and physiological hyperarousal. In contrast, proactive or instrumental aggression is goal-driven, rewarding, and associated with hypoarousal (126); it is not a model for irritability. A hyperaroused RA rodent model can be created using alcohol or anabolic steroid exposure, frustration, or priming by exposure to an opponent (120). In non-human primates, the Human Intruder Paradigm can be used to model RA (127). Human data finding associations between irritability and autonomic hyperarousal at baseline and after frustration demonstrate the translational potential of such models (83,98). Human research could be extended using other arousal measures, including actigraphy and pupillometry. Rodent studies of RA implicate the amygdala, and possibly the medial PFC, findings generally consistent with human literature (120,123).

In irritability and other clinical domains, one barrier to clinically-relevant cross-species research is that clinical pathophysiological studies focus on inter-individual differences, i.e. why are some

people more irritable than others? However, such inter-individual differences remain understudied in animals; exceptions include differences in aggressive or anxiety-related threat responses (128,129). Given the central role of frustration in irritability, the highest priority studies would examine inter-individual differences in FNR in animals. Human experimental medicine studies that pair a therapeutic intervention with mechanistic approaches parallel animal studies of mean intra-individual changes in response to an experimental (vs. control) intervention; these provide another possible translational bridge. More cross-talk between clinical researchers using neuroimaging to study irritability and animal researchers interested in the topic could foster the development of novel interventions.

Future research directions

Irritability research has progressed. Significant advances have occurred in defining the scope and nature of the clinical problem; creating developmentally-sensitive tools that measure irritability specifically; identifying developmental trajectories; confronting diagnostic challenges; leveraging clear clinical connections between frustration and irritability into mechanistic studies; obtaining preliminary treatment data; and elucidating genetic associations.

However, given the relatively recent focus on irritability, it is unsurprising that much work remains (Table 1); five overarching research priorities emerge. The first is the need for studies in large, diverse samples of the impact of cultural and social context on the presentation of irritability, parental responses, and children's experience. There has been related research on

the broader construct of ED (130), and international efforts are being organized to undertake research in irritability.

A second major research need concerns the external validity of the irritability construct and the measurement tools used to assess it. This requires going beyond self- and parent-report and confronting the general lack of agreement in psychology between subject report and biomarkers such as brain imaging or physiology (131). However, since self- and parent-report will always be essential to the clinical endeavor, a third research need is for greater understanding of the factors driving differences in informant reports (30,42).

A fourth major research priority encompasses understanding the transdiagnostic nature of irritability. One important and tractable question is whether treatments targeting irritability also diminish co-occurring symptoms such as ADHD, depression, or anxiety. An underlying mechanistic question regards the extent to which irritability present in different clinical contexts is mediated by similar brain mechanisms.

Finally and importantly, the evidence base for treatment needs to be expanded by rigorously conducted, well-powered RCTs that either re-purpose existing treatments or test novel interventions. More mechanistic work is needed to guide the development of novel interventions. Regarding mechanism, neuroimaging studies would benefit from the adoption of multiple methodological advances, and increased cross-talk is needed between clinical researchers and those doing relevant basic and translational research (111,114). While this lays

out an ambitious research agenda, the scope and importance of the clinical problem, coupled with recent advances laying groundwork for future studies, warrant the investment.

References

1. Evans SC, Corteselli KA, Edelman A, Scott H, Weisz JR. Is Irritability a Top Problem in Youth Mental Health Care? A Multi-informant, Multi-method Investigation. *Child Psychiatry Hum Dev* [Internet]. 2022 Jan 22 [cited 2022 Dec 2]; Available from: <https://link.springer.com/10.1007/s10578-021-01301-8>
2. Carlson GA, Singh MK, Amaya-Jackson L, Benton TD, Althoff RR, Bellonci C, et al. Narrative Review: Impairing Emotional Outbursts: What They Are and What We Should Do About Them. *J Am Acad Child Adolesc Psychiatry*. 2022 Mar;S089085672200123X.
3. Carlson GA, Singh MK. Emotion Dysregulation and Outbursts in Children and Adolescents: Part I. *Child Adolesc Psychiatr Clin N Am*. 2021 Apr;30(2):xiii–xvi.
4. Laporte PP, Matijasevich A, Munhoz TN, Santos IS, Barros AJD, Pine DS, et al. Disruptive Mood Dysregulation Disorder: Symptomatic and Syndromic Thresholds and Diagnostic Operationalization. *J Am Acad Child Adolesc Psychiatry*. 2021 Feb;60(2):286–95.
5. Stringaris A, Vidal-Ribas P, Brotman MA, Leibenluft E. Practitioner Review: Definition, recognition, and treatment challenges of irritability in young people. *J Child Psychol Psychiatry*. 2018 Jul;59(7):721–39.
6. Conner CM, Golt J, Shaffer R, Righi G, Siegel M, Mazefsky CA. Emotion Dysregulation is Substantially Elevated in Autism Compared to the General Population: Impact on Psychiatric Services. *Autism Res*. 2021 Jan;14(1):169–81.
7. Brotman MA, Kircanski K, Stringaris A, Pine DS, Leibenluft E. Irritability in Youths: A Translational Model. *Am J Psychiatry*. 2017 Jun;174(6):520–32.
8. Barker ED, Salekin RT. Irritable oppositional defiance and callous unemotional traits: is the association partially explained by peer victimization?: Irritable opposition. *J Child Psychol Psychiatry*. 2012 Nov;53(11):1167–75.
9. Bielas H, Barra S, Skrivanek C, Aebi M, Steinhausen HC, Bessler C, et al. The associations of cumulative adverse childhood experiences and irritability with mental disorders in detained male adolescent offenders. *Child Adolesc Psychiatry Ment Health*. 2016 Dec;10(1):34.
10. Pagliaccio D, Pine DS, Barch DM, Luby JL, Leibenluft E. Irritability Trajectories, Cortical Thickness, and Clinical Outcomes in a Sample Enriched for Preschool Depression. *J Am Acad Child Adolesc Psychiatry*. 2018 May;57(5):336–342.e6.
11. Kircanski K, Craske MG, Averbeck BB, Pine DS, Leibenluft E, Brotman MA. Exposure therapy for pediatric irritability: Theory and potential mechanisms. *Behav Res Ther*. 2019 Jul;118:141–9.

12. Roy AK, Comer JS. Advances in the Conceptualization, Assessment, and Treatment of Pediatric Irritability. *Behav Ther.* 2020 Mar;51(2):207–10.
13. Mood. In: *APA Dictionary of Psychology* [Internet]. Available from: <https://dictionary.apa.org/mood>
14. Mazefsky CA, Yu L, Pilkonis PA. Psychometric Properties of the Emotion Dysregulation Inventory in a Nationally Representative Sample of Youth. *J Clin Child Adolesc Psychol.* 2021 Sep 3;50(5):596–608.
15. Zik J, Deveney CM, Ellingson JM, Haller SP, Kircanski K, Cardinale EM, et al. Understanding Irritability in Relation to Anger, Aggression, and Informant in a Pediatric Clinical Population. *J Am Acad Child Adolesc Psychiatry.* 2022 May;61(5):711–20.
16. Nigg JT, Karalunas SL, Feczko E, Fair DA. Toward a Revised Nosology for Attention-Deficit/Hyperactivity Disorder Heterogeneity. *Biol Psychiatry Cogn Neurosci Neuroimaging.* 2020 Aug;5(8):726–37.
17. Kendler KS. A history of the DSM-5 scientific review committee. *Psychol Med.* 2013 Sep;43(9):1793–800.
18. Leibenluft E, Kircanski K. Chronic Irritability in Youth. *Child Adolesc Psychiatr Clin N Am.* 2021 Jul;30(3):667–83.
19. Stringaris A, Zavos H, Leibenluft E, Maughan B, Eley TC. Adolescent Irritability: Phenotypic Associations and Genetic Links With Depressed Mood. *Am J Psychiatry.* 2012 Jan;169(1):47–54.
20. Merwood A, Chen W, Rijdsdijk F, Skirrow C, Larsson H, Thapar A, et al. Genetic Associations Between the Symptoms of Attention-Deficit/Hyperactivity Disorder and Emotional Lability in Child and Adolescent Twins. *J Am Acad Child Adolesc Psychiatry.* 2014 Feb;53(2):209–220.e4.
21. Roberson-Nay R, Leibenluft E, Brotman MA, Myers J, Larsson H, Lichtenstein P, et al. Longitudinal Stability of Genetic and Environmental Influences on Irritability: From Childhood to Young Adulthood. *Am J Psychiatry.* 2015 Jul;172(7):657–64.
22. Vidal-Ribas P, Brotman MA, Valdivieso I, Leibenluft E, Stringaris A. The Status of Irritability in Psychiatry: A Conceptual and Quantitative Review. *J Am Acad Child Adolesc Psychiatry.* 2016 Jul;55(7):556–70.
23. Benton TD, Muhrer E, Jones JD, Lewis J. Dysregulation and Suicide in Children and Adolescents. *Child Adolesc Psychiatr Clin N Am.* 2021 Apr;30(2):389–99.
24. Galera C, Orri M, Vergunst F, Melchior M, Van der Waerden J, Bouvard MP, et al. Developmental profiles of childhood attention-deficit/hyperactivity disorder and

- irritability: association with adolescent mental health, functional impairment, and suicidal outcomes. *J Child Psychol Psychiatry*. 2021 Feb;62(2):232–43.
25. Cornacchio D, Crum KI, Cox S, Pincus DB, Comer JS. Irritability and Severity of Anxious Symptomatology Among Youth With Anxiety Disorders. *J Am Acad Child Adolesc Psychiatry*. 2016 Jan;55(1):54–61.
 26. Wiggins JL, Briggs-Gowan MJ, Estabrook R, Brotman MA, Pine DS, Leibenluft E, et al. Identifying Clinically Significant Irritability in Early Childhood. *J Am Acad Child Adolesc Psychiatry*. 2018 Mar;57(3):191-199.e2.
 27. Leibenluft E. Severe Mood Dysregulation, Irritability, and the Diagnostic Boundaries of Bipolar Disorder in Youths. *Am J Psychiatry*. 2011 Feb;168(2):129–42.
 28. Cardinale EM, Freitag GF, Brotman MA, Pine DS, Leibenluft E, Kircanski K. Phasic Versus Tonic Irritability: Differential Associations With Attention-Deficit/Hyperactivity Disorder Symptoms. *J Am Acad Child Adolesc Psychiatry*. 2021 Dec;60(12):1513–23.
 29. Silver J, Carlson GA, Olin T, Perlman G, Mackin D, Kotov R, et al. Differential outcomes of tonic and phasic irritability in adolescent girls. *J Child Psychol Psychiatry*. 2021 Oct;62(10):1220–7.
 30. Linke JO, Haller SP, Xu E, Nguyen LT, Chue AE, Botz-Zapp C, et al. Persistent Frustration-Induced Reconfigurations of Brain Networks Predict Individual Differences in Irritability. *J Am Acad Child Adolesc Psychiatry*. 2022 Dec;S0890856722019827.
 31. Ametti MR, Crehan ET, O’Loughlin K, Schreck MC, Dube SL, Potter AS, et al. Frustration, Cognition, and Psychophysiology in Dysregulated Children: A Research Domain Criteria Approach. *J Am Acad Child Adolesc Psychiatry*. 2022 Jun;61(6):796-808.e2.
 32. Dodge KA. The structure and function of reactive and proactive aggression. In: *The development and treatment of childhood aggression*. Lawrence Erlbaum Associates, Inc.; 1991. p. 201–18.
 33. Qi S, Nielson DM, Marcotulli D, Pine D, Stringaris A. Subjective Affective Experience under threat is shaped by environmental affordances [Internet]. *PsyArXiv*; 2023 Jun [cited 2023 Aug 8]. Available from: <https://osf.io/vaq3k>
 34. Mingebach T, Kamp-Becker I, Christiansen H, Weber L. Meta-meta-analysis on the effectiveness of parent-based interventions for the treatment of child externalizing behavior problems. Botbol M, editor. *PLOS ONE*. 2018 Sep 26;13(9):e0202855.
 35. Yu Q, Hodgdon EA, Kryza-Lacombe M, Osuna L, Bozzetto LE, Ciro D, et al. Roads Diverged: Developmental Trajectories of Irritability From Toddlerhood Through Adolescence. *J Am Acad Child Adolesc Psychiatry*. 2023 Nov;S0890856722019013.

36. Evans SC, Burke JD, Roberts MC, Fite PJ, Lochman JE, de la Peña FR, et al. Irritability in child and adolescent psychopathology: An integrative review for ICD-11. *Clin Psychol Rev*. 2017 Apr;53:29–45.
37. Goodman R, Ford T, Richards H, Gatward R, Meltzer H. The Development and Well-Being Assessment: Description and Initial Validation of an Integrated Assessment of Child and Adolescent Psychopathology. *J Child Psychol Psychiatry*. 2000 Jul;41(5):645–55.
38. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): Initial Reliability and Validity Data. *J Am Acad Child Adolesc Psychiatry*. 1997 Jul;36(7):980–8.
39. Althoff RR, Ametti M. Measurement of Dysregulation in Children and Adolescents. *Child Adolesc Psychiatr Clin N Am*. 2021 Apr;30(2):321–33.
40. Carlson GA, Silver J, Klein DN. Psychometric Properties of the Emotional Outburst Inventory (EMO-I): Rating What Children Do When They Are Irritable. *J Clin Psychiatry* [Internet]. 2022 Jan 25 [cited 2023 Jan 27];83(2). Available from: <https://www.psychiatrist.com/jcp/mental/child/psychometric-properties-emotional-outburst-inventory-emo-i-rating-what-children-do-when-they-are-irritable/>
41. Mazefsky CA, Conner CM, Breitenfeldt K, Leezenbaum N, Chen Q, Bylsma LM, et al. Evidence Base Update for Questionnaires of Emotion Regulation and Reactivity for Children and Adolescents. *J Clin Child Adolesc Psychol*. 2021 Nov 2;50(6):683–707.
42. Mallidi A, Meza-Cevera T, Kircanski K, Stringaris A, Brotman MA, Pine DS, et al. Informant-discrepancy in the Affective Reactivity Index Reflects the Multifaceted Nature of Childhood and Adolescent Irritability [Internet]. *PsyArXiv*; 2022 Aug [cited 2022 Dec 7]. Available from: <https://osf.io/gdh7s>
43. De Los Reyes A, Epkins CC. Introduction to the Special Issue. A Dozen Years of Demonstrating That Informant Discrepancies are More Than Measurement Error: Toward Guidelines for Integrating Data from Multi-Informant Assessments of Youth Mental Health. *J Clin Child Adolesc Psychol*. 2023 Jan 2;52(1):1–18.
44. Althoff RR, Rettew DC, Ayer LA, Hudziak JJ. Cross-informant agreement of the Dysregulation Profile of the Child Behavior Checklist. *Psychiatry Res*. 2010 Aug;178(3):550–5.
45. Achenbach TM, Rescorla L. Manual for the ASEBA school-age forms and profiles. University of Vermont Research Center for Children, Youth, and Families; 2001.
46. Orri M, Galera C, Turecki G, Boivin M, Tremblay RE, Geoffroy MC, et al. Pathways of Association Between Childhood Irritability and Adolescent Suicidality. *J Am Acad Child Adolesc Psychiatry*. 2019 Jan;58(1):99-107.e3.

47. Wiggins JL, Mitchell C, Stringaris A, Leibenluft E. Developmental Trajectories of Irritability and Bidirectional Associations With Maternal Depression. *J Am Acad Child Adolesc Psychiatry*. 2014 Nov;53(11):1191-1205.e4.
48. Riglin L, Eyre O, Thapar AK, Stringaris A, Leibenluft E, Pine DS, et al. Identifying Novel Types of Irritability Using a Developmental Genetic Approach. *Am J Psychiatry*. 2019 Aug;176(8):635–42.
49. Boylan K, Rowe R, Duku E, Waldman I, Stepp S, Hipwell A, et al. Longitudinal Profiles of Girls' Irritable, Defiant and Antagonistic Oppositional Symptoms: Evidence for Group Based Differences in Symptom Severity. *J Abnorm Child Psychol*. 2017 Aug;45(6):1133–45.
50. Ezpeleta L, Granero R, de la Osa N, Trepát E, Domènech JM. Trajectories of Oppositional Defiant Disorder Irritability Symptoms in Preschool Children. *J Abnorm Child Psychol*. 2016 Jan;44(1):115–28.
51. Copeland WE, Angold A, Costello EJ, Egger H. Prevalence, Comorbidity, and Correlates of DSM-5 Proposed Disruptive Mood Dysregulation Disorder. *Am J Psychiatry*. 2013 Feb;170(2):173–9.
52. Orri M, Galera C, Turecki G, Forte A, Renaud J, Boivin M, et al. Association of Childhood Irritability and Depressive/Anxious Mood Profiles With Adolescent Suicidal Ideation and Attempts. *JAMA Psychiatry*. 2018 May 1;75(5):465.
53. Wakschlag LS, Choi SW, Carter AS, Hullsiek H, Burns J, McCarthy K, et al. Defining the developmental parameters of temper loss in early childhood: implications for developmental psychopathology: Early childhood parameters of temper loss. *J Child Psychol Psychiatry*. 2012 Nov;53(11):1099–108.
54. Biederman J, Klein RG, Pine DS, Klein DF. Resolved: mania is mistaken for ADHD in prepubertal children. *J Am Acad Child Adolesc Psychiatry*. 1998 Oct;37(10):1091–6; discussion 1096-1099.
55. Moreno C, Laje G, Blanco C, Jiang H, Schmidt AB, Olfson M. National Trends in the Outpatient Diagnosis and Treatment of Bipolar Disorder in Youth. *Arch Gen Psychiatry*. 2007 Sep 1;64(9):1032.
56. Findling RL, Zhou X, George P, Chappell PB. Diagnostic Trends and Prescription Patterns in Disruptive Mood Dysregulation Disorder and Bipolar Disorder. *J Am Acad Child Adolesc Psychiatry*. 2022 Mar;61(3):434–45.
57. Wiggins JL, Briggs-Gowan MJ, Brotman MA, Leibenluft E, Wakschlag LS. Toward a Developmental Nosology for Disruptive Mood Dysregulation Disorder in Early Childhood. *J Am Acad Child Adolesc Psychiatry*. 2021 Mar;60(3):388–97.

58. Brotman MA, Schmajuk M, Rich BA, Dickstein DP, Guyer AE, Costello EJ, et al. Prevalence, Clinical Correlates, and Longitudinal Course of Severe Mood Dysregulation in Children. *Biol Psychiatry*. 2006 Nov;60(9):991–7.
59. Dougherty LR, Smith VC, Bufferd SJ, Carlson GA, Stringaris A, Leibenluft E, et al. DSM-5 disruptive mood dysregulation disorder: correlates and predictors in young children. *Psychol Med*. 2014 Aug;44(11):2339–50.
60. Dougherty LR, Smith VC, Bufferd SJ, Kessel EM, Carlson GA, Klein DN. Disruptive mood dysregulation disorder at the age of 6 years and clinical and functional outcomes 3 years later. *Psychol Med*. 2016 Apr;46(5):1103–14.
61. Althoff RR, Crehan ET, He JP, Burstein M, Hudziak JJ, Merikangas KR. Disruptive Mood Dysregulation Disorder at Ages 13–18: Results from the National Comorbidity Survey—Adolescent Supplement. *J Child Adolesc Psychopharmacol*. 2016 Mar;26(2):107–13.
62. Munhoz TN, Santos IS, Barros AJD, Anselmi L, Barros FC, Matijasevich A. Perinatal and postnatal risk factors for disruptive mood dysregulation disorder at age 11: 2004 Pelotas Birth Cohort Study. *J Affect Disord*. 2017 Jun;215:263–8.
63. Chen YL, Chen WJ, Lin KC, Shen LJ, Gau SSF. Prevalence of DSM-5 mental disorders in a nationally representative sample of children in Taiwan: methodology and main findings. *Epidemiol Psychiatr Sci*. 2020;29:e15.
64. Lin YJ, Tseng WL, Gau SSF. Psychiatric comorbidity and social adjustment difficulties in children with disruptive mood dysregulation disorder: A national epidemiological study. *J Affect Disord*. 2021 Feb;281:485–92.
65. Herzhoff K, Tackett JL. Subfactors of oppositional defiant disorder: converging evidence from structural and latent class analyses. *J Child Psychol Psychiatry*. 2016 Jan;57(1):18–29.
66. Polanczyk GV, Salum GA, Sugaya LS, Caye A, Rohde LA. Annual Research Review: A meta-analysis of the worldwide prevalence of mental disorders in children and adolescents. *J Child Psychol Psychiatry*. 2015 Mar;56(3):345–65.
67. Kotov R, Krueger RF, Watson D, Achenbach TM, Althoff RR, Bagby RM, et al. The Hierarchical Taxonomy of Psychopathology (HiTOP): A dimensional alternative to traditional nosologies. *J Abnorm Psychol*. 2017 May;126(4):454–77.
68. Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, et al. Research Domain Criteria (RDoC): Toward a New Classification Framework for Research on Mental Disorders. *Am J Psychiatry*. 2010 Jul;167(7):748–51.
69. Finlay-Jones AL, Ang JE, Brook J, Lucas JD, MacNeill LA, Mancini VO, et al. Systematic Review and Meta-analysis: Early Irritability as a Transdiagnostic Neurodevelopmental

Vulnerability to Later Mental Health Problems. *J Am Acad Child Adolesc Psychiatry*. 2023 Feb;S0890856723000771.

70. Krogh-Jespersen S, Kaat AJ, Petitclerc A, Perlman SB, Briggs-Gowan MJ, Burns JL, et al. Calibrating temper loss severity in the transition to toddlerhood: Implications for developmental science. *Appl Dev Sci*. 2022 Oct 2;26(4):785–98.
71. Lind T, Bernard K, Ross E, Dozier M. Intervention effects on negative affect of CPS-referred children: Results of a randomized clinical trial. *Child Abuse Negl*. 2014 Sep;38(9):1459–67.
72. Smith JD, Wakschlag L, Krogh-Jespersen S, Walkup JT, Wilson MN, Dishion TJ, et al. Dysregulated Irritability as a Window on Young Children’s Psychiatric Risk: Transdiagnostic Effects via the Family Check-Up. *Dev Psychopathol*. 2019 Dec;31(5):1887–99.
73. Quiñones-Camacho LE, Fishburn FA, Camacho MC, Hlutkowsky CO, Huppert TJ, Wakschlag LS, et al. Parent–child neural synchrony: a novel approach to elucidating dyadic correlates of preschool irritability. *J Child Psychol Psychiatry*. 2020 Nov;61(11):1213–23.
74. Perlman SB, Jones BM, Wakschlag LS, Axelson D, Birmaher B, Phillips ML. Neural substrates of child irritability in typically developing and psychiatric populations. *Dev Cogn Neurosci*. 2015 Aug;14:71–80.
75. Wakschlag LS, Roberts MY, Flynn RM, Smith JD, Krogh-Jespersen S, Kaat AJ, et al. Future Directions for Early Childhood Prevention of Mental Disorders: A Road Map to Mental Health, Earlier. *J Clin Child Adolesc Psychol*. 2019 May 4;48(3):539–54.
76. Shimshoni Y, Lebowitz ER, Brotman MA, Pine DS, Leibenluft E, Silverman WK. Anxious-Irritable Children: A Distinct Subtype of Childhood Anxiety? *Behav Ther*. 2020 Mar;51(2):211–22.
77. Benarous X, Consoli A, Cohen D, Renaud J, Lahaye H, Guilé JM. Suicidal behaviors and irritability in children and adolescents: a systematic review of the nature and mechanisms of the association. *Eur Child Adolesc Psychiatry*. 2019 May;28(5):667–83.
78. Srinivasan R, Flouri E, Lewis G, Solmi F, Stringaris A, Lewis G. Changes in Early Childhood Irritability and Its Association With Depressive Symptoms and Self-Harm During Adolescence in a Nationally Representative United Kingdom Birth Cohort. *J Am Acad Child Adolesc Psychiatry*. 2023 Jun;S0890856723003441.
79. Harty SC, Gnagy EM, Pelham WE, Molina BSG. Anger-irritability as a mediator of attention deficit hyperactivity disorder risk for adolescent alcohol use and the contribution of coping skills. *J Child Psychol Psychiatry*. 2017 May;58(5):555–63.
80. Silver J, Mackin DM, Bufferd SJ, Dougherty LR, Goldstein BL, Carlson GA, et al. Tonic and phasic irritability in 6-YEAR-OLD CHILDREN : differential correlates and outcomes. *J Child Psychol Psychiatry*. 2022 Aug 27;jcpp.13688.

81. Karalunas SL, Gustafsson HC, Fair D, Musser ED, Nigg JT. Do we need an irritable subtype of ADHD? Replication and extension of a promising temperament profile approach to ADHD subtyping. *Psychol Assess*. 2019 Feb;31(2):236–47.
82. Salazar de Pablo G, Pastor Jordá C, Vaquerizo-Serrano J, Moreno C, Cabras A, Arango C, et al. Systematic Review and Meta-analysis: Efficacy of Pharmacological Interventions for Irritability and Emotional Dysregulation in Autism Spectrum Disorder and Predictors of Response. *J Am Acad Child Adolesc Psychiatry*. 2022 Apr;S0890856722001988.
83. Carter Leno V, Forth G, Chandler S, White P, Yorke I, Charman T, et al. Behavioural and physiological response to frustration in autistic youth: associations with irritability. *J Neurodev Disord*. 2021 Dec;13(1):27.
84. Wakschlag LS, Perlman SB, Blair RJ, Leibenluft E, Briggs-Gowan MJ, Pine DS. The Neurodevelopmental Basis of Early Childhood Disruptive Behavior: Irritable and Callous Phenotypes as Exemplars. *Am J Psychiatry*. 2018 Feb;175(2):114–30.
85. Gardner F, Montgomery P, Knerr W. Transporting Evidence-Based Parenting Programs for Child Problem Behavior (Age 3–10) Between Countries: Systematic Review and Meta-Analysis. *J Clin Child Adolesc Psychol*. 2016 Nov;45(6):749–62.
86. Sukhodolsky DG, Kassinove H, Gorman BS. Cognitive-behavioral therapy for anger in children and adolescents: a meta-analysis. *Aggress Violent Behav*. 2004 May;9(3):247–69.
87. Evans SC, Weisz JR, Carvalho AC, Garibaldi PM, Bearman SK, Chorpita BF, et al. Effects of standard and modular psychotherapies in the treatment of youth with severe irritability. *J Consult Clin Psychol*. 2020 Mar;88(3):255–68.
88. Breaux R, Baweja R, Eadeh HM, Shroff DM, Cash AR, Swanson CS, et al. Systematic Review and Meta-analysis: Pharmacological and Non-pharmacological Interventions for Persistent Non-episodic Irritability. *J Am Acad Child Adolesc Psychiatry*. 2022 Jun;S0890856722003033.
89. Kircanski K, Clayton ME, Leibenluft E, Brotman MA. Psychosocial Treatment of Irritability in Youth. *Curr Treat Options Psychiatry*. 2018 Mar;5(1):129–40.
90. Perepletchikova F, Nathanson D, Axelrod SR, Merrill C, Walker A, Grossman M, et al. Randomized Clinical Trial of Dialectical Behavior Therapy for Preadolescent Children With Disruptive Mood Dysregulation Disorder: Feasibility and Outcomes. *J Am Acad Child Adolesc Psychiatry*. 2017 Oct;56(10):832–40.
91. Miller L, Hlastala SA, Mufson L, Leibenluft E, Yenokyan G, Riddle M. Interpersonal psychotherapy for mood and behavior dysregulation: Pilot randomized trial. *Depress Anxiety*. 2018 Jun;35(6):574–82.

92. Naim R, Kircanski K, Gold A, German RE, Davis M, Perlstein S, et al. Across-subjects multiple baseline trial of exposure-based cognitive-behavioral therapy for severe irritability: a study protocol. *BMJ Open*. 2021 Mar;11(3):e039169.
93. Krebs G, Bolhuis K, Heyman I, Mataix-Cols D, Turner C, Stringaris A. Temper outbursts in paediatric obsessive-compulsive disorder and their association with depressed mood and treatment outcome. *J Child Psychol Psychiatry*. 2013 Mar;54(3):313–22.
94. Stoddard J, Zik J, Mazefsky CA, DeChant B, Gabriels R. The Internal Structure of the Aberrant Behavior Checklist Irritability Subscale: Implications for Studies of Irritability in Treatment-Seeking Youth With Autism Spectrum Disorders. *Behav Ther*. 2020 Mar;51(2):310–9.
95. Cohen D, Bonnot O, Bodeau N, Consoli A, Laurent C. Adverse Effects of Second-Generation Antipsychotics in Children and Adolescents: A Bayesian Meta-Analysis. *J Clin Psychopharmacol*. 2012 Jun;32(3):309–16.
96. Fernández de la Cruz L, Simonoff E, McGough JJ, Halperin JM, Arnold LE, Stringaris A. Treatment of Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and Irritability: Results From the Multimodal Treatment Study of Children With ADHD (MTA). *J Am Acad Child Adolesc Psychiatry*. 2015 Jan;54(1):62–70.e3.
97. Towbin K, Vidal-Ribas P, Brotman MA, Pickles A, Miller KV, Kaiser A, et al. A Double-Blind Randomized Placebo-Controlled Trial of Citalopram Adjunctive to Stimulant Medication in Youth With Chronic Severe Irritability. *J Am Acad Child Adolesc Psychiatry*. 2020 Mar;59(3):350–61.
98. Naim R, Goodwin MS, Dombek K, Revzina O, Agorsor C, Lee K, et al. Cardiovascular reactivity as a measure of irritability in a transdiagnostic sample of youth: Preliminary associations. *Int J Methods Psychiatr Res* [Internet]. 2021 Dec [cited 2023 Mar 20];30(4). Available from: <https://onlinelibrary.wiley.com/doi/10.1002/mpr.1890>
99. Marek S, Tervo-Clemmens B, Calabro FJ, Montez DF, Kay BP, Hatoum AS, et al. Reproducible brain-wide association studies require thousands of individuals. *Nature*. 2022 Mar 24;603(7902):654–60.
100. Lee KS, Hagan CN, Hughes M, Cotter G, McAdam Freud E, Kircanski K, et al. Systematic Review and Meta-analysis: Task-based fMRI Studies in Youths With Irritability. *J Am Acad Child Adolesc Psychiatry*. 2022 Aug;S0890856722012278.
101. Nielsen AN, Wakschlag LS, Norton ES. Linking irritability and functional brain networks: A transdiagnostic case for expanding consideration of development and environment in RDoC. *Neurosci Biobehav Rev*. 2021 Oct;129:231–44.
102. DeSerisy M, Deveney CM. Behavioral and Psychophysiological Investigations of Irritability. In: Roy AK, Brotman MA, Leibenluft E, editors. *Irritability in Pediatric Psychopathology*

[Internet]. Oxford University Press; 2019 [cited 2022 Dec 7]. p. 45–70. Available from: <https://academic.oup.com/book/1199/chapter/140036365>

103. Camacho MC, Wakschlag LS, Perlman SB. Early Childhood Irritability: Using a Neurodevelopmental Framework to Inform Clinical Understanding. In: Roy AK, Brotman MA, Leibenluft E, editors. Irritability in Pediatric Psychopathology [Internet]. Oxford University Press; 2019 [cited 2022 Dec 7]. p. 73–93. Available from: <https://academic.oup.com/book/1199/chapter/140037091>
104. Savage J, Verhulst B, Copeland W, Althoff RR, Lichtenstein P, Roberson-Nay R. A Genetically Informed Study of the Longitudinal Relation Between Irritability and Anxious/Depressed Symptoms. *J Am Acad Child Adolesc Psychiatry*. 2015 May;54(5):377–84.
105. Mikolajewski AJ, Taylor J, Iacono WG. Oppositional defiant disorder dimensions: genetic influences and risk for later psychopathology. *J Child Psychol Psychiatry*. 2017 Jun;58(6):702–10.
106. Burt SA. Rethinking environmental contributions to child and adolescent psychopathology: A meta-analysis of shared environmental influences. *Psychol Bull*. 2009;135(4):608–37.
107. Nigg JT, Karalunas SL, Gustafsson HC, Bhatt P, Ryabinin P, Mooney MA, et al. Evaluating chronic emotional dysregulation and irritability in relation to ADHD and depression genetic risk in children with ADHD. *J Child Psychol Psychiatry*. 2020 Feb;61(2):205–14.
108. Plomin R, Viding E. Commentary: Will genomics revolutionise research on gene–environment interplay? *J Child Psychol Psychiatry*. 2022 Oct;63(10):1214–8.
109. Patterson G. Coercive family process. Eugene Castalia. 1982;
110. Moore AA, Lapato DM, Brotman MA, Leibenluft E, Aggen SH, Hettema JM, et al. Heritability, stability, and prevalence of tonic and phasic irritability as indicators of disruptive mood dysregulation disorder. *J Child Psychol Psychiatry*. 2019 Apr 17;jcpp.13062.
111. Amsel A. The role of frustrative nonreward in noncontinuous reward situations. *Psychol Bull*. 1958;55(2):102–19.
112. Koolhaas JM, Coppens CM, de Boer SF, Buwalda B, Meerlo P, Timmermans PJA. The Resident-intruder Paradigm: A Standardized Test for Aggression, Violence and Social Stress. *J Vis Exp*. 2013 Jul 4;(77):4367.
113. Tseng W, Naim R, Chue A, Shaughnessy S, Meigs J, Pine DS, et al. Network analysis of ecological momentary assessment identifies frustration as a central node in irritability. *J Child Psychol Psychiatry*. 2023 Aug;64(8):1212–21.

114. Martín-García E, Fernández-Castillo N, Burokas A, Gutiérrez-Cuesta J, Sánchez-Mora C, Casas M, et al. Frustrated expected reward induces differential transcriptional changes in the mouse brain: Microarrays and frustration. *Addict Biol.* 2015 Jan;20(1):22–37.
115. Guarino S, Conrad SE, Papini MR. Frustrative nonreward: Chemogenetic inactivation of the central amygdala abolishes the effect of reward downshift without affecting alcohol intake. *Neurobiol Learn Mem.* 2020 Mar;169:107173.
116. Burokas A, Gutiérrez-Cuesta J, Martín-García E, Maldonado R. Operant model of frustrated expected reward in mice: Model of frustration in mice. *Addict Biol.* 2012 Jul;17(4):770–82.
117. Vasquez TES, Shah P, Re JD, Laezza F, Green TA. Individual Differences in Frustrative Nonreward Behavior for Sucrose in Rats Predict Motivation for Fentanyl under Progressive Ratio. *eneuro.* 2021 Sep;8(5):ENEURO.0136-21.2021.
118. Naik AA, Munyeshyaka M, Ma X, Leibenluft E, Li Z. A New Behavioral Paradigm for Studying Frustrative Non-reward in Juvenile Mice [Internet]. *Neuroscience*; 2023 Mar [cited 2023 Mar 20]. Available from: <http://biorxiv.org/lookup/doi/10.1101/2023.02.28.530477>
119. Falkner AL, Grosenick L, Davidson TJ, Deisseroth K, Lin D. Hypothalamic control of male aggression-seeking behavior. *Nat Neurosci.* 2016 Apr;19(4):596–604.
120. Flanigan ME, Russo SJ. Recent advances in the study of aggression. *Neuropsychopharmacology.* 2019 Jan;44(2):241–4.
121. Kircanski K, White LK, Tseng WL, Wiggins JL, Frank HR, Sequeira S, et al. A Latent Variable Approach to Differentiating Neural Mechanisms of Irritability and Anxiety in Youth. *JAMA Psychiatry.* 2018 Jun 1;75(6):631.
122. Bertsch K, Florange J, Herpertz SC. Understanding Brain Mechanisms of Reactive Aggression. *Curr Psychiatry Rep.* 2020 Dec;22(12):81.
123. Leibenluft E. Pediatric Irritability: A Systems Neuroscience Approach. *Trends Cogn Sci.* 2017 Apr;21(4):277–89.
124. Naim R, Haller SP, Linke JO, Jaffe A, Stoddard J, Jones M, et al. Context-dependent amygdala–prefrontal connectivity during the dot-probe task varies by irritability and attention bias to angry faces. *Neuropsychopharmacology.* 2022 Dec;47(13):2283–91.
125. Hommer RE, Meyer A, Stoddard J, Connolly ME, Mogg K, Bradley BP, et al. Attention Bias to Threat Faces in Severe Mood Dysregulation. *Depress Anxiety.* 2014 Jul;31(7):559–65.
126. Aubry AV, Joseph Burnett C, Goodwin NL, Li L, Navarrete J, Zhang Y, et al. Sex differences in appetitive and reactive aggression. *Neuropsychopharmacology.* 2022 Sep;47(10):1746–54.

127. Kalin NH, Shelton SE. Defensive Behaviors in Infant Rhesus Monkeys: Environmental Cues and Neurochemical Regulation. *Science*. 1989 Mar 31;243(4899):1718–21.
128. Popa N, Bachar D, Roberts AC, Santangelo AM, Gascon E. Region-specific microRNA alterations in marmosets carrying SLC6A4 polymorphisms are associated with anxiety-like behavior. *eBioMedicine*. 2022 Aug;82:104159.
129. Takahashi A, Aleyasin H, Stavarache MA, Li L, Cathomas F, Parise LF, et al. Neuromodulatory effect of interleukin 1 β in the dorsal raphe nucleus on individual differences in aggression. *Mol Psychiatry*. 2022 May;27(5):2563–79.
130. Di Giunta L, Rothenberg WA, Lunetti C, Lansford JE, Pastorelli C, Eisenberg N, et al. Longitudinal associations between mothers' and fathers' anger/irritability expressiveness, harsh parenting, and adolescents' socioemotional functioning in nine countries. *Dev Psychol*. 2020 Mar;56(3):458–74.
131. Harrewijn A, Vidal-Ribas P, Clore-Gronenborn K, Jackson SM, Pisano S, Pine DS, et al. Associations between brain activity and endogenous and exogenous cortisol – A systematic review. *Psychoneuroendocrinology*. 2020 Oct;120:104775.